---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-26-000020"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:18:20.292063+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lisata to be acquired by Kuva Labs for $5.00 per share plus contingent $1.00 CVR

## Summary
- Kuva Labs will acquire all Lisata common shares for $5.00 cash plus one non-tradeable CVR potentially paying $1.00 upon FDA filing for certepetide.
- CVR milestone: payable if NDA is filed/accepted for certepetide within 7 years of closing; Parent must use commercially reasonable efforts.
- Unanimous board recommendation; tender offer with minimum tender condition of majority of outstanding shares (including rollover shares).
- Termination fee of $2M payable by either party under certain circumstances; no financing condition to the offer.
- In-the-money options, restricted stock, and RSUs cashed out at Closing Amount plus CVR; ESPP terminated at closing.

## SEC filing metadata
- accession: 0000320017-26-000020
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001726000020/0000320017-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001726000020/clbs-20260306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-26-000020
- JSON: https://secwatch.observer/filing/0000320017-26-000020.json
- Plain text: https://secwatch.observer/filing/0000320017-26-000020.txt

## Source-grounded claims
- claim_id: 16394058a3e161422c4f57792560d901309035b4
  claim: LISATA THERAPEUTICS, INC. entered into Agreement and Plan of Merger with Kuva Labs Inc. (effective 2026-03-06).
  evidence_excerpt: On March 6, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “Company” or “Lisata”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kuva Labs Inc., a Delaware corporation (“Parent”), and Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001726000020/0000320017-26-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.